Payment overview · 2025
General Payments
$79.83
2 reported records · 2 companies
Healthcare provider profile · identity verified
Scott D Booker, DO
Allopathic & Osteopathic Physicians|Family Medicine · GARDEN CITY, KS · NPI 1447216411
Verified facts
What the public records show
CMS Open Payments records show Scott D Booker, DO received $79.83 in general payments during 2025 across 2 reported records.
Medtronic, Inc. accounted for 80.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$64.45 | 80.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.38 | 19.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $79.83 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $64.45 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 191 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
191 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1105 | 223 |
| Losartan Potassium | Losartan Potassium | 620 | 136 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 537 | 130 |
| Amlodipine Besylate | Amlodipine Besylate | 534 | 123 |
| Potassium Chloride | Potassium Chloride | 484 | 102 |
| Atorvastatin Calcium | Atorvastatin Calcium | 371 | 71 |
| Furosemide | Furosemide | 315 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 308 | 58 |
| Duloxetine Hcl | Duloxetine Hcl | 297 | 45 |
| Gabapentin | Gabapentin | 291 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 273 | 50 |
| Warfarin Sodium | Warfarin Sodium | 270 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 252 | 49 |
| Omeprazole | Omeprazole | 241 | 54 |
| Mirtazapine | Mirtazapine | 233 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 221 | 52 |
| Famotidine | Famotidine | 209 | 48 |
| Metformin Hcl | Metformin Hcl | 199 | 40 |
| Meloxicam | Meloxicam | 198 | 54 |
| Lisinopril | Lisinopril | 193 | 40 |
| Ozempic | Semaglutide | 191 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 191 | 44 |
| Alprazolam | Alprazolam | 180 | 40 |
| Sertraline Hcl | Sertraline Hcl | 171 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 168 | 37 |
| Trazodone Hcl | Trazodone Hcl | 166 | 33 |
| Simvastatin | Simvastatin | 164 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 159 | 34 |
| Xarelto | Rivaroxaban | 148 | 18 |
| Allopurinol | Allopurinol | 140 | 32 |
| Eliquis | Apixaban | 132 | 18 |
| Spironolactone | Spironolactone | 131 | 33 |
| Metformin Hcl Er | Metformin Hcl | 128 | 33 |
| Amoxicillin | Amoxicillin | 123 | 88 |
| Clopidogrel | Clopidogrel Bisulfate | 119 | 29 |
| Tramadol Hcl | Tramadol Hcl | 116 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 115 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 105 | 26 |
| Carvedilol | Carvedilol | 101 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 101 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 95 | 25 |
| Finasteride | Finasteride | 89 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 33 |
| Memantine Hcl | Memantine Hcl | 87 | 12 |
| Alendronate Sodium | Alendronate Sodium | 84 | 20 |
| Ezetimibe | Ezetimibe | 83 | 22 |
| Synthroid | Levothyroxine Sodium | 83 | 14 |
| Azithromycin | Azithromycin | 82 | 59 |
| Donepezil Hcl | Donepezil Hcl | 81 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 81 | 14 |
| Montelukast Sodium | Montelukast Sodium | 80 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 79 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 75 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 27 |
| Clonazepam | Clonazepam | 65 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 64 | 43 |
| Gemfibrozil | Gemfibrozil | 62 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 11 |
| Glipizide Er | Glipizide | 61 | 11 |
| Sucralfate | Sucralfate | 61 | 13 |
| Olanzapine | Olanzapine | 58 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 56 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 55 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 54 | suppressed |
| Nifedipine Er | Nifedipine | 52 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 51 | suppressed |
| Fentanyl | Fentanyl | 51 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 50 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 50 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | 11 |
| Lovastatin | Lovastatin | 47 | suppressed |
| Atenolol | Atenolol | 42 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 11 |
| Prednisone | Prednisone | 42 | 12 |
| Baclofen | Baclofen | 41 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 41 | suppressed |
| Bumetanide | Bumetanide | 40 | suppressed |
| Celecoxib | Celecoxib | 39 | suppressed |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 37 | suppressed |
| Jardiance | Empagliflozin | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 37 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 28 |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Klor-Con M20 | Potassium Chloride | 34 | suppressed |
| Lorazepam | Lorazepam | 34 | suppressed |
| Digoxin | Digoxin | 33 | suppressed |
| Glimepiride | Glimepiride | 33 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 33 | 23 |
| Torsemide | Torsemide | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 21 |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 21 |
| Solifenacin Succinate | Solifenacin Succinate | 30 | suppressed |
| Fluconazole | Fluconazole | 29 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 28 | suppressed |
| Methotrexate | Methotrexate Sodium | 28 | suppressed |
| Levofloxacin | Levofloxacin | 27 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Repatha Sureclick | Evolocumab | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 19 |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 23 | 18 |
| Estradiol | Estradiol | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 15 |
| Glipizide | Glipizide | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 20 | 20 |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Invokamet | Canagliflozin/Metformin Hcl | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 16 |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 17 | 17 |
| Haloperidol | Haloperidol | 17 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Nystatin | Nystatin | 17 | 12 |
| Acetazolamide | Acetazolamide | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 16 | suppressed |
| Calcium Acetate | Calcium Acetate | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Repatha Syringe | Evolocumab | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Oxycontin | Oxycodone Hcl | 15 | suppressed |
| Praluent Pen | Alirocumab | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 14 | suppressed |
| Cimetidine | Cimetidine | 14 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Letrozole | Letrozole | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Entacapone | Entacapone | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Exelon | Rivastigmine | 12 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $79.83 · 2 records | Medtronic, Inc. | INTELLIS ADAPTIVESTIM, Ozempic, Rybelsus | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error